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Abstract: In our previous study, we found that trans-2-decenoic acid ethyl ester (DAEE), a 
derivative of a medium-chain fatty acid, elicits neurotrophin-like signals including the 
activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in cultured mouse 
cortical neurons. Here, we examined the efficacy of intraperitoneal administration of 
DAEE on the treatment of a mouse model of the cerebral infarction caused by unilateral 
permanent middle cerebral artery occlusion (PMCAO). DAEE-treatment (100 µg/kg body 
weight injected at 0.5, 24, 48, 72 h after PMCAO) significantly restored the mice from 
PMCAO-induced neurological deficits including motor paralysis when evaluated 48, 72, 
and 96 h after the PMCAO. Furthermore, DAEE facilitated the phosphorylation of   
ERK1/2 on the infarction side of the brain when analyzed by Western immunoblot 
analysis, and it enhanced the number of phosphorylated ERK1/2-positive cells in the 
border areas between the infarction and non-infarction regions of the cerebral cortex, as 
estimated immunohistochemically. As the infarct volume remained unchanged after 
DAEE-treatment, it is more likely that DAEE improved the neurological condition through 
enhanced neuronal functions of the remaining neurons in the damaged areas rather than by 
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maintaining neuronal survival. These results suggest that DAEE has a neuro-protective 
effect on cerebral infarction. 
Keywords: 2-decenoic acid ethyl ester; neurotrophin; extracellular signal-regulated kinases 
1 and 2; cerebral infarction 
 
1. Introduction 
Previously, we demonstrated that medium-chain fatty acids (MCFAs) with 8–12 carbons and their 
esters facilitated activation (phosphorylation) of extracellular signal-regulated kinases 1 and 2 
(ERK1/2) in cultured embryonic cortical neurons [1,2]. In particular, trans-2-decenoic acid ethyl ester 
(DAEE: C12H22O2 = 198.30: Figure 1) has the most potent activity among these compounds, and 
causes the activation of intracellular signal molecules other than ERK1/2 such as Akt and   
cAMP-responsive element binding protein (CREB), a transcription factor, suggesting that DAEE has 
neurotrophin-like activities on neurons and thus may be a promising therapeutic tool for certain 
neurological disorders including cerebral infarction. 
Figure 1. The chemical structure of trans-2-decenoic acid ethyl ester (DAEE).  
 
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, and it stimulates 
neuronal differentiation and maintains survival of various neuronal populations. Recent investigations 
revealed a relationship between BDNF and various neurological disorders such as Parkinson’s   
disease [3], Alzheimer’s disease [4], depression [5], and anxiety-related personal trait [6].   
These findings suggest the availability of BDNF as a therapeutic tool for particular neurological 
disorders, and BDNF has been successfully tested in animal models of various diseases. However, 
clinical trials have been less successful at demonstrating therapeutic efficacy [7]. Many technical and 
pharmacological issues, for instance, instability of the protein and/or a lack of an appropriate   
delivery system, remain unsolved. To overcome these problems, the development of stable and small 
molecules with BDNF-like activity that pass through the blood-brain barrier may represent an 
alternative approach.  
Stroke is the third commonest cause of death in industrialized countries, leading disability in adult 
and elderly individuals [8]. Cerebral infarction is caused by occlusion of the cerebral arteries [9], and 
vascular reperfusion therapy is the most effective tool for the prevention of brain injury and reduction 
of mortality in patients with acute cerebral infarction. In addition to the reperfusion therapy, 
establishment of effective neuroprotective therapies have been anticipated. For instance, edaravone, a 
strong free radical scavenger, is considered to have a preventive effect against cerebral infarction [10]. Int. J. Mol. Sci. 2012, 13  4970 
 
 
However, the major functional mechanism of edaravone is based on reducing the secondary damage 
caused by free radicals generated after ischemia. A novel therapeutic tool that can act on neurons 
directly and preserve their function would contribute to the improvement of the prognosis of patients 
with cerebral infarction. DAEE may be one such candidate, because it is a compound that can generate 
neurotrophin-like signals. Therefore, we examined the ameliorative or therapeutic effects of DAEE on 
a mouse model of the cerebral infarction caused by unilateral permanent middle cerebral artery 
occlusion (PMCAO). 
2. Results 
2.1. Evaluation of Functional Recovery after PMCAO 
Recovery of the locomotor function of the right side of body was evaluated by using the scale 
described later. 
Figure 2. Improvement of neurological conditions by the treatment with DAEE. Values 
were assessed at 24, 48, 72, and 96 h after permanent middle cerebral artery occlusion 
(PMCAO). Significance: * P < 0.05, ** P < 0.01 vs. vehicle with Mann-Whitney U test  
(n = 58 [DAEE group] or 60 [vehicle control]). No significant difference was observed in 
mortality (score = 4) by use of Chi-square test.  
 
PMCAO resulted in moderate motor paralysis of the contralateral side (scale: 2) 0.5 h after the 
occlusion. Recovery from the motor paralysis was significantly enhanced by intraperitoneal 
administration of DAEE compared with the paralysis seen in the vehicle-treated group, when evaluated 
48, 72, and 96 h after PMCAO. The neurological condition was thus improved in the DAEE-treated 
group. That is, improvement of the locomotor function from scale 2 to scale 1 occurred earlier in the Int. J. Mol. Sci. 2012, 13  4971 
 
 
DAEE-treated group than in the vehicle-treated group (Figure 2). The survival rate of 96 h after 
PMCAO was higher in the DAEE-treated group than that of the vehicle-treated group (91.7% vs. 
84.5%, respectively), however, no significant difference was observed (P = 0.23, Chi-square test). 
2.2. Measurement of Infarct Volume 
Next we examined the infarct volume by staining with 2,3,5-triphenyltetrazolium chloride (TTC; 
Sigma-Aldrich, Saint Louis, MO, USA) to assess the effect of DAEE treatment quantitatively 96 h 
after PMCAO. TTC reacts with intact mitochondrial respiratory enzymes to generate a bright-red color 
that stand in contrast with the pale color of an infarction [11,12]. As the borderlines between normal 
and infarct areas cannot be detected in microscopic view by TTC staining, Nissl staining is applicable 
to designate the ischemic region histochemically [13]. The infarction range detected by TTC is 
perceived to be the same as that detected by Nissl staining. So, we confirmed that the borderlines 
determined by Nissl staining almost corresponded to those by TTC staining at the microscopic level. 
Although neuronal death had occurred in the infarct area, no significant differences in the infarct area 
or volume were found between vehicle- and DAEE-treated groups (Figure 3).  
Figure 3. Cerebral infarction after PMCAO in vehicle- or DAEE-treated mice.   
(A) 2,3,5-triphenyltetrazolium chloride (TTC) staining of coronal brain sections (2-mm 
thick) obtained 96 h after PMCAO from the vehicle-control mice; (B) TTC staining of 
coronal brain sections (2-mm thick) obtained 96 h after PMCAO from the DAEE–treated 
mice; (C) Brain infarct area measured 96 h after PMCAO. Brains were removed, and the 
forebrains were sliced into five coronal 2-mm sections. The section numbers correspond to 
the numbers of “A” and “B”. The brain infarct area was not significantly different between 
the two groups (vs. vehicle; Student’s t-test; n = 6 or 5). The values are expressed as the 
means ± SEs; (D) Brain infarct volume measured 96 h after PMCAO. There was no 
significant difference in infarct volume between both groups (Student’s t-test; n = 6 or 5). 
The values are expressed as the means ± SEs.  
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2.3. Activation of ERK1/2 
Activation of ERK1/2 by PMCAO was assessed by Western blot analysis with specific antibody 
against ERK1/2 or phosphorylated ERK1/2 (pERK1/2). DAEE-treatment significantly raised the level 
of pERK1/2 4 days after PMCAO to one higher than that of the vehicle-treatment group (Figure 4-A). 
Figure 4. Level and distribution of pERK1/2 in the infracted brain after vehicle- or   
DAEE-treatment. (A) Immunoblot profiles of pERK1/2 (a-1) and ERK1/2 (a-2) of the 
vehicle- and DAEE-treated infarct brain 96 h after PMCAO. b: Quantitative analysis of the 
ratio of the intensity of the band of pERK1/2 to that of ERK1/2. The values are expressed 
as the means ± SEs (n = 6). Significance: * P  < 0.05 vs.  vehicle (Student’s t-test).  
(B) Photographs “a” to “d” showed Nissl stained profiles, and “e” and “f” are 
immunostained ones by anti-pERK1/2. Photographs “a” and “b” are Nissl stained profiles 
taken with low-power-magnification. The boxes in photograph “a” and “b” include the 
border region between infarct and non-infarct areas, and enlarged as shown in photographs 
“c” and “d”. Photographs “a” and “c” are profiles obtained from the vehicle-treated group 
and “b” and “d”, from the DAEE-treated group. The scale bar for both photographs is  
500 µm. The dotted lines in photographs “c” and “d” indicate the borderlines between the 
infarction and non-infarction areas that were determined in terms of the Nissl-positive cell 
density. Photographs “e” and “f” are profiles taken from the adjacent sections 
immunostained for pERK1/2 in the vehicle- and DAEE-treated groups, respectively. The 
same dotted lines shown in “c” and “d” were drawn on the photographs “e” and “f”. The 
scale bar indicated in “c” is 100 µm and also applicable to “d”–“f”. The pERK1/2-positive 
cells were counted in the 3 regions, i.e., the infarction area lateral to the borderline 
(photograph “g”), the ischemic penumbra on the borderline (photograph “h”), and the 
normal area medial to the borderline (photograph “i”). Each count was expressed as the 
number of pERK1/2-positive cells/ (200 × 200) µm
2. These cells, indicated by the arrows 
in photograph “f”, were significantly greater in number in the ischemic penumbra at the 
borderline (* P < 0.05 vs. vehicle; Student’s t-test; n = 3) in the DAEE-treated group than 
in the vehicle-treated group. However, in the other 2 areas (normal and ischemic), there 
were no significant differences between the 2 groups (vs. vehicle; Student’s t-test; n = 3).  
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Figure 4. Cont. 
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2.4. Expression of pERK1/2 in Ischemic Penumbra 
Nissl staining was performed to determine the border between the normal and infarct areas. The 
Nissl-positive cells were defined as the cells with a diameter of 10 µm or more. We regarded the 
normal area as that where the density of Nissl-positive cells was over 5 cells/50 × 50 µm
2; and the 
infarct area, as the region with a lower cell density. In this way, we could get polygonal lines. So, we 
drew curves through the midpoints of each straight line of them fitted by eye. Therefore, we defined 
the curve as the borderline between the normal and infarct areas. On each consecutive slice, the 
number of pERK1/2-positive cells was counted in the normal, infarct, and border areas. We counted 
the numbers in a square area 200 µm on a side with a focus on the borderline as the border area, in the 
same sized square just medial to the border area as the normal area, and in the square just lateral to it 
as the infarct area. These areas were counted in high-powered fields on a section through the anterior 
commissure. Each count was expressed as number of pERK1/2-positive cells/200 × 200 µm
2 (n = 3). 
In the DAEE-treated group, pERK1/2-positive cells were observed in the border area between the 
infarct and normal areas, namely, in the area containing Nissl stained neurons, in the cerebral cortex. 
On the other hand, in the vehicle-treated group, pERK1/2-positive cells in the border area were 
significantly fewer than those in the DAEE-treated group. The numbers of the pERK1/2-positive cells 
in the other areas, i.e., normal and infarct areas, were not significantly different between the two 
groups (Figure 4-B).  
  Int. J. Mol. Sci. 2012, 13  4974 
 
 
2.5. Expression of BDNF mRNAs after PMCAO 
The mRNA expression of BDNF was investigated by reverse transcription-polymerase chain 
reaction (RT-PCR). DAEE-treatment significantly raised the expression of BDNF 96 h after PMCAO 
higher than that of the vehicle-treatment group (Figure 5). 
Figure 5. mRNA expression of BDNF in the infracted brain after vehicle- or   
DAEE-treatment. (A) The electrophoresis profiles of BDNF (A-1) and β-actin (A-2) of the 
vehicle- and DAEE-treated infarct brain 96 h after PMCAO; (B) Quantitative analysis of 
the ratio of the intensity of the band of BDNF to that of β-actin. The values are expressed 
as the means ± SEs (n = 5–6). Significance: * P < 0.05 vs. vehicle (Student’s t-test).  
 
3. Discussion 
The present results demonstrated the beneficial effects of DAEE on functional recovery after 
PMCAO, although no significant differences in mortality rate were observed between DAEE and 
vehicle group 96 h after PMCAO. Furthermore, the size of the infarct area was not significantly 
different between DAEE- and vehicle- treated groups. It was conspicuous, however, that the level of 
pERK1/2 in the hemisphere with the infarction was elevated in the DAEE-treated group when judged 
by Western blotting. The immunohistochemical results confirmed this observation by demonstrating 
that there were more pERK1/2-positive cells in the DAEE-treated group than in the vehicle-treated 
group around the borderline (ischemic penumbra) in the cerebral cortex. These results suggest that 
DAEE preserved the neuronal function in the ischemic penumbra through the activation of ERK1/2 to 
stimulate expression of neurotrophins and thus contributed to functional recovery. As DAEE did not 
significantly reduce the infarct size in TTC- and/or Nissl-stained sections, it remains uncertain whether 
or not DAEE treatment could rescue neurons from dying. 
It is well known that ERK1/2 mediates the expression of neuroprotective activity of extracellular 
neurotrophic factors including neurotrophins. In the nervous system, ERK1/2 is critical for neuronal Int. J. Mol. Sci. 2012, 13  4975 
 
 
differentiation and synapse plasticity and may also modulate neuronal survival. Activation of ERK1/2 
protects neurons by compensating for the deleterious effects of a damaging insult [14]. The present 
study showed that pERK1/2-positive cells were localized in the border area between normal and 
infarct areas in the DAEE-treated group, suggesting that DAEE promoted the activation of ERK1/2 in 
the neurons damaged by ischemia, perhaps resulting in protection against neuronal death. 
In the present study, we found that DAEE did not affect the infarct volume. Jiang et al. indicated 
that BDNF protects neurons against an ischemic insult without affecting the infarct volume estimated 
by TTC staining [15]. However, they indicated that BDNF prevents the loss of neurons detected by 
Nissl staining, in the border between normal and infarct areas [15]. Their results suggest that BDNF 
does not reduce the infarct volume when the gross appearance is observed after TTC staining but that 
this neurotrophic factor has the ability to prevent neuronal cell loss in the border area when observed 
microscopically. Therefore, DAEE may also preserve the survival and function of neuronal cells 
through the activation of ERK1/2 in the ischemic penumbra. 
DAEE-treatment enhanced the expression of BDNF mRNAs in present study. These results indicate 
that DAEE through increased BDNF expression improves the functional recovery after cerebral 
infarction. Even though DAEE increases the BDNF mRNA (Figure 5), this would not affect the 
infarction but rather improve the neurological function.  
 In recent years, evidence has been reported to indicate that omega-3 polyunsaturated fatty acids 
(PUFAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have therapeutic 
potential in animal models of various neuronal disorders [16–18]. Although limited information is 
available about the effect of MCFAs on neuronal cells, some recent reports have described such 
effects. For instance, MCFAs facilitate neurite outgrowth of PC12 cells through the activation of 
MAPK (p38 mitogen-activated protein kinase)/ERK1/2 pathways [19]; and 10-hydroxy-trans   
2-decenoic acid stimulates the neurogenesis of cultured neural stem/progenitor cells, partly mimicking 
the effect of BDNF [20]. 
Neurotrophins such as BDNF bind to a specific TrkB receptor tyrosine kinase [21], which causes 
autophosphorylation of the TrkB receptor to trigger signal transduction cascades including the 
pathways of MAPK/ERK1/2, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ [22]. These 
signals then pass into the nucleus to activate transcription factors such as CREB, which activation 
leads to the expression of genes that regulate neuronal functions. The mechanism of DAEE action is 
unclear at present. However, we have found that DAEE has the ability to stimulate the phosphorylation 
of epidermal growth factor receptor (EGFR) and of ErbB2 (Abe et al., unpublished results). Although 
it is unclear at present whether TrkB is involved in the putative action mechanism, it is likely that 
DAEE stimulated the phosphorylation of ERK1/2 in concentration- and time-dependent manners, and 
activated Akt located in downstream of PI3K, and CREB through activation of EGFR and/or   
ErbB2. These observations suggest that DAEE behaves like EGF or vascular endothelial growth   
factor (VEGF).  
Neurotrophic factors including BDNF and EGF have been considered as regulators of neuronal 
survival and differentiation during development and for maintenance of neuronal functions in 
adulthood, including synaptic plasticity [23]. Some reports about the beneficial effects of BDNF on 
cerebral ischemic models were published earlier [24,25]. Furthermore, Ferrer et al. reported that 
BDNF specifically up-regulates its full-length TrkB receptor in cortical neurons in the penumbra area Int. J. Mol. Sci. 2012, 13  4976 
 
 
in a rat model of focal ischemia [9]; and Jiang et al. indicated that BDNF protects the brain against 
ischemic insult by modulating local inflammation via regulation of the levels of cellular cytokines and 
transcription factors in a rat model of PMCAO [15]. However, the clinical trials have been less 
successful because of many technical and pharmacological issues [26]. These considerations suggest 
promising availability of DAEE as a therapeutic tool for particular neurological disorders. 
Furthermore, Hirakwa et al. found beneficial effects of DAEE on locomotor function after a spinal 
cord injury in rats [2].  
Nowadays, oxidative stress is considered to be a principal factor promoting brain damage after 
ischemia. A prime goal of neuroprotective strategy is thus to reduce oxidative damage. In fact, 
edaravone, a radical scavenger, has been approved as a neuroprotective agent against acute cerebral 
infarction in Japan [8]. Recent investigations have revealed that propofol, a potent intravenously 
delivered hypnotic agent, also protects the brain against ischemic injury, by reducing cerebral blood 
flow, cerebral oxygen metabolism, and intracranial pressure by scavenging free radicals and by 
decreasing lipid peroxidation [27]. The mechanism underlying the beneficial effects of DAEE on 
neuronal cells would be different from these mechanisms. In some reports about the effects of 
edaravone on cerebral infarction, the effective doses of edaravone is 1.5–9 mg/kg body weight in 
animal models [28–30]. And clinical dose of it is 2.4 mg/kg patients [30]. Compared with these doses 
of edaravone, the effective dose of DAEE for mice model of cerebral infarction was extremely low 
(100 µg/kg) in this study. It also indicates the effectiveness of DAEE. 
We previously found that the phosphorylation level of ERK1/2 in the cerebral cortex   
and hippocampus was facilitated in the mice received DAEE intraperitoneally compared with   
vehicle-treated mice (Makino et al., unpublished data). These results suggest permeability of DAEE 
and related active conpound through blood-brain barrier. DAEE is a stable molecule with neurotrophic 
activities, overcoming the various problems of instability and lack of an appropriate delivery system 
that remain to be problematic with BDNF; and it has novel functional mechanisms of neuroprotection 
that are different from those of substances and drugs already known. In consideration of these 
attributes, appending DAEE-treatment to the existing therapy for cerebral infarction may improve the 
prognosis of the patients. 
4. Experimental Section  
4.1. Animal Model of Cerebral Infarction 
The experiments were conducted in accordance with the Animal Care Guidance issued by the 
Animal Experiments Committee of the graduate school of Gifu University and Gifu Pharmaceutical 
University. All experiments were performed by using male ddY mice (5-week old; body weight 27 to 
33 g) purchased from Japan SLC Ltd., (Shizuoka, Japan). Cerebral infarction was produced by 
permanent occlusion of the left middle cerebral artery. Anesthesia was induced using 2.0 to 3.0% 
isoflurane and maintained by using 1.5 to 2.0% isoflurane with 70% N2O/30% O2 delivered by means 
of an animal general anesthesia machine (Soft Lander, Sin-ei Industry Co Ltd., Saitama, Japan). The 
regional cerebral blood flow in each mouse was monitored by laser-Doppler flowmetry (Omega-Flow 
flo-N1; Omegawave Inc., Tokyo, Japan). A flexible probe was fixed to the skull (2 mm posterior and  Int. J. Mol. Sci. 2012, 13  4977 
 
 
6 mm lateral to bregma). After a midline skin incision had been made, the left common carotid artery 
was exposed and occluded. An 8-0 nylon monofilament (Eticon, Somerville, NJ, USA) coated with a 
mixture of silicone resin (Provil; Hereus Kulzer Inc., Hanau, Germany) was introduced into the left 
common carotid artery and advanced it along the internal carotid artery until the tip occluded the 
proximal stem of the middle cerebral artery, as described earlier [31,32]. 
4.2. Administration of the Drug  
DAEE was purchased from Sigma-Aldrich Co. LLC. DAEE was dissolved in 0.1% dimethylsulfoxide 
(DMSO; Wako Pure Chemical Industries Ltd., Osaka, Japan) and diluted with phosphate-buffered 
saline (PBS). It was administered intraperitoneally into the animals at a dose of 100 µg/kg at 0.5, 24, 48, 
and 72 h after PMCAO. Control animals received vehicle (PBS) containing 0.1% DMSO without DAEE. 
4.3. Analysis of Animal Behavior  
Mice (vehicle; n = 58, DAEE; n = 60) were tested for neurological deficits, as described earlier [31] 
at 0.5, 24, 48, 72, and 96 h after PMCAO. Scoring was done by using the following scale: 0, no 
observable neurological deficits (normal); 1, failure to extend the right forepaw (mild); 2, circling to 
the contralateral side (moderate); 3, loss of walking or righting reflex (severe); 4, dead. The 
investigators were masked as to the group to which each mouse belonged. 
4.4. Measurement of Infarct Volume 
The brains were removed immediately after the mice had been given an overdose of diethyl ether, at 
96 h after PMCAO, and cut into 5 serial 2-mm-thick coronal block slices. These slices were immersed 
for 20 min in a 2% solution of TTC. Image J software was used to measure the unstained areas of the 
total infarctions, and the infarction volume was calculated as described previously [31]. 
4.5. Western Immunoblot Analysis 
The brains were dissected out as described in the previous section. The left hemisphere of the anterior  
4th slice was used for Western blotting. Tissues were homogenized in lysis buffer (20 mM Tris-HCl, pH 
7.4, containing 150 mM NaCl, 2 mM EDTA, 1% NP-40, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 50 mM 
NaVO4, 1 mM phenylmethylsulfonyl fluoride [PMSF], 0.1% sodium dodecyl sulfate [SDS] and 1% Na 
deoxycholate) and then centrifuged, after which the supernatant fluids were collected. Protein 
concentrations of the supernatants were determined with a BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL, USA). Each sample, 2.8 µg protein for ERK1/2 and 7.0 µg protein for pERK1/2 was 
subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene 
fluoride membranes by electrophoresis. The membranes were blocked for 1 h at room temperature with 5% 
skim milk (Morinaga Milk Products, Tokyo, Japan) in Tris-buffered saline containing 0.1% Tween 20 
(TBS/Tween 20) and then incubated with primary antibody against ERK1/2 or pERK1/2 (1:1000, Cell 
Signaling Technology, Beverly, MA, USA) for 2 h. After having been washed with TBS/Tween 20, the 
membranes were incubated with alkaline phosphatase-conjugated anti-rabbit IgG secondary antibody 
(1:5000 Promega, Madison, WI, USA) for 3 h. Finally the specific protein bands were developed with nitro Int. J. Mol. Sci. 2012, 13  4978 
 
 
blue tetrazolium and 5-bromo-4-chloro-3-indrylphosphate p-toluidine salt. The intensity of immunoreactive 
bands was measured by use of image-analysis software (NIH Image J). 
4.6. Histopathological and Immunohistchemical Study 
Brains were removed after cardio-perfusion with 4% (w/v) paraformaldehyde solution prepared in 
0.1 M phosphate buffer, pH 7.4 (fixative), 96 h after PMCAO, postfixed in the same fixative 
overnight, soaked in PBS containing 20% (w/v) sucrose, and frozen in embedding compound (Sakura 
Finetek, Tokyo, Japan). Coronal sections of 30-µm thickness were prepared with a cryostat (model 
CM 1800; Leica, Nussloch, Germany), attached to adhesive-coated slides (Matsunami, Osaka, Japan), 
dried, and soaked in the above fixative for 30 min.  
The sections were stained for Nissl substance with 0.1% thionin, dehydrated by passage through an 
ascending series of ethanol, cleared in xylene, and coverslipped with Euikit (O. Kindler, Freiburg, 
Germany) [33]. For immunohistochemistry with the chromogen diaminobenzidine (DAB), the sections 
were treated with TBS/0.3% Triton X-100 containing 0.3% H2O2 for 3 h, rinsed for 1 h in the same 
solution, washed 3 times with TBS and blocked for 30 min with 2% (w/v) Block Ace (Dainippon 
Sumitomo Pharma Co. Ltd., Osaka, Japan) dissolved in TBS (blocking solution). Next, the sections 
were incubated overnight at 4 °C with antibody against pERK1/2 (1:1000; Chemicon, Temecula, CA, 
USA). After a wash with TBS, the sections were incubated for 3 h with anti-rabbit IgG goat antibody 
(1:1000; Vector Laboratories, Burlingame, CA, USA). The sections were then incubated in ABC 
solution (Elite ABC, Vector Laboratories) with gentle shaking at 4 °C overnight and further treated 
according to the glucose oxidase-DAB-nickel method. Finally the sections were stained with   
3,3′-diaminobenzidine tetrahydrochloride (Dojindo Laboratories, Kumamoto, Japan) for 5–10 min. 
4.7. RT-PCR 
The brains were dissected out as described in the previous section. The left hemisphere of the 
anterior 4th slice was used for RT-PCR experiment. RNA was prepared from the collected tissues by 
using TRIZOL (Invirtogen, Carlsbad, CA, USA) according to the manufacture’s instructuins. RT-PCR 
was performed with PowerScript
TM Reverse Transcriptase (Clontech, CA, USA) by following the 
manufacturer’s instructions. The synthesized cDNAs were amplified with each pair of primers by PCR. 
The following primer sets were used: β-actin, 5′-GTGGGCCGCTCTAGGCACCAA-3′ and 5′-
CTCTTTGATATCACGCACGAT-3′ BDNF, 5′-GGAATTCGAGTGATGACCATCCTTTTCCTTAC-
3′ and 5′-CGGATCCCTATCTTCCCCTTTTAATGGTCAGTG-3′. The amplification was carried out 
under the following conditions: denaturation, 94 °C for 45 s; annealing, 63 °C (for β-actin) or 65 °C 
(for BDNF) for 45 s; and extension, 72 °C for 45 s. The cycle was repeated 26 times for β-actin,  
33 times for BDNF. β-actin was used as an internal control. PCR products were electrophoresed in 2% 
agarose gels and visualized by Ethidium Bromide staining. The intensity of the bands was analyzed by 
used of image-analysis software (NIH Image J). 
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4.8. Statistical Analysis 
Statistical comparisons were made using two-way analysis of variance followed by Mann-Whitney 
U test, Chi-square test, or Student’s t-test. 
5. Conclusions  
We presently found that DAEE acted to facilitate functional recovery of locomotion activity after 
PMCAO. These findings suggest the possibility that DAEE will become a promising tool for   
cerebral infarction. 
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